Davita Inc vs Skyworks Solutions Inc — how do they compare? Davita Inc trades at $179.24 (market cap $11.29B), while Skyworks Solutions Inc trades at $76.35 (market cap $12.15B). The key difference: Davita Inc and Skyworks Solutions Inc are close in size by market cap, and Skyworks Solutions Inc pays a 4.13% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Skyworks Solutions Inc for 50 Days on average.
| DVA | SWKS | |
|---|---|---|
Market Cap | $11.29B | $12.15B |
Volume | 582,204 | 7,390,810 |
Sector | Health | Technology |
52-Week High | $240.96 | $91.45 |
52-Week Low | $103.87 | $52.50 |
Typical Hold Time | 113 Days | 50 Days |
Enterprise Value | $24.01B | $12.03B |
Dividend Yield | — | 4.13% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
Skyworks Solutions (SWKS) trades at $83.43, up 0.88% on the day, with a neutral technical signal despite bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, though revenue and net income margins have declined year-over-year. The pending Qorvo merger, expected to close in 2026, represents a significant strategic move with $500 million in projected synergies, driving recent stock momentum and analyst optimism.
The investment case balances merger synergies and market expansion against declining profitability and integration risks. With 60% of analysts rating SWKS a Buy and a consensus price target of $78.80 (below current price), near-term upside appears limited. Key risks include execution of the Qorvo integration, competitive pressures in semiconductors, and macroeconomic headwinds affecting consumer electronics demand.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →